Human absorbed dose estimation for a new (175)Yb-phosphonate based on rats data: Comparison with similar bone pain palliation agents

Mahdokht Vaez-Tehrani; Samaneh Zolghadri; Hassan Yousefnia; Hossein Afarideh

doi:10.1016/j.apradiso.2016.06.013

Human absorbed dose estimation for a new (175)Yb-phosphonate based on rats data: Comparison with similar bone pain palliation agents

Appl Radiat Isot. 2016 Sep:115:55-60. doi: 10.1016/j.apradiso.2016.06.013. Epub 2016 Jun 14.

Authors

Mahdokht Vaez-Tehrani¹, Samaneh Zolghadri², Hassan Yousefnia², Hossein Afarideh¹

Affiliations

¹ Energy Engineering and Department of Physics, Amir Kabir University of Technology, Tehran, Iran.
² Nuclear Science and Technology Research Institute (NSTRI), 14155-1339 Tehran, Iran.

PMID: 27337650
DOI: 10.1016/j.apradiso.2016.06.013

Abstract

In this work, the absorbed dose to human organs for (175)Yb-BPAMD was evaluated based on the biodistribution studies in rats. The results showed that the bone surface would receive the highest absorbed dose after injection of (175)Yb-BPAMD with 13.32mGy/MBq, while the other organs receive insignificant absorbed dose. Also, the comparison of (175)Yb-BPAMD with other therapeutic phosphonate complexes demonstrated noticeable characteristics for this new agent. Generally, based on the obtained results, (175)Yb-BPAMD can be considered as a promising agent for bone pain palliative therapy in near future.

Keywords: Absorbed dose; BPAMD; RADAR; Ytterbium-175.

MeSH terms

Animals
Bone Neoplasms / complications
Humans
Organophosphonates / pharmacokinetics*
Pain / drug therapy*
Pain Management
Radiation Dosage
Rats
Tissue Distribution
Ytterbium

Substances

Organophosphonates
Ytterbium